VRTX logo

VRTX Vertex Pharmaceuticals Incorporated

NASDAQ Global Select · Biotechnology · Healthcare

$515.02
-5.64 (-1.08%)

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance r…

Market Cap: $130.58Bwww.vrtx.com

Price

$496.07+16.07%
$423.92$459.14$494.37$529.59
Apr 30Aug 7

Social Signal Score

59
5d
70
1 mentions
+0.0%
30d
54
28 mentions
+0.0%
60d
55
46 mentions
+0.0%
90d
57
60 mentions
+0.0%
news: 27 · rss: 29 · 4chan: 2 · marketaux: 2

Analyst Ratings

56 analysts
Buyconsensus
Strong Buy 0Buy 49Hold 6Sell 1Strong Sell 0
Avg price target$579.29+12.5%
Low $350Median $608High $665
Current Consensus

Revenue

$3.44B+650.11%
$458.71M$1.45B$2.45B$3.44B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$18.48
$17.96–$18.80
18 analysts
FY2026
$18.16-2% YoY
$17.65–$19.17
17 analysts
FY2027
$19.95+10% YoY
$18.13–$21.45
17 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Reshma Kewalramani
Sector
Healthcare
Industry
Biotechnology
Employees
6,400
Beta
0.32
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
8.43
www.vrtx.com